O6-methylguanine-DNA methyltransferase hypermethylation modulated by 17β-estradiol in lung cancer cells

Ji Ching Lai, Jeng Yuan Wu, Ya Wen Cheng, Kun Tu Yeh, Tzu Chin Wu, Chih Yi Chen, Huei Lee

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: Our recent report indicated that MGMT hypermethylation is more common in squamous cell carcinomas (SCC) in males, and smokers than in adenocarcinomas (ADC) infernales, and nonsmokers. More interestingly, MGMT hypermethylation in SCC and ADC was pronouncedly influenced by gender factor, not by smoking status. We questioned whether 17β-estradiol could modulate the machinery of promoter methylation to cause the gender difference of MGMT hypermethylation in lung cancer. Materials and Methods: Two MGMT hypermethylated Ch27 and H1355 lung cancer cell lines were treated with or without 17β-estradiol and the status of hypermethylation was examined by methylated specific methylation (MSP) as compared with both cells treated with demethylating agents, 5-AZA-dC (AZA) or TSA. Results: Our data showed that 17β-estradiol, similar to AZA, diminished the MGMT hypermethylation and restored MGMT mRNA expression, which was not observed in the case of TSA. Western blotting showed that 17β-estradiol markedly reduced DNMT1 expression in Ch27 and H1355 cells, but slightly reduced HDAC1 expression. Consequently, acetylated H3 and H4 histone levels were slightly increased by 17β-estradiol in both cell types. In addition, ChIP analysis revealed that 17β-estradiol simultaneously diminished the binding activity of both proteins on the MGMT promoter of both cell lines. Conclusion: 17β-Estradiol decreased DNMT1 and HDAC1 protein expressions and their binding activity on MGMT promoter, and this may partially contribute to the gender difference of MGMT hypermethylation in lung cancer.

Original languageEnglish
Pages (from-to)2535-2540
Number of pages6
JournalAnticancer Research
Volume29
Issue number7
Publication statusPublished - Jul 2009
Externally publishedYes

Fingerprint

Methyltransferases
Estradiol
Lung Neoplasms
DNA
Histones
Methylation
Squamous Cell Carcinoma
Adenocarcinoma
Cell Line
O-(6)-methylguanine
Proteins
Western Blotting
Smoking
Messenger RNA

Keywords

  • Gender difference
  • MGMT
  • NSCLC
  • p53 mutation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lai, J. C., Wu, J. Y., Cheng, Y. W., Yeh, K. T., Wu, T. C., Chen, C. Y., & Lee, H. (2009). O6-methylguanine-DNA methyltransferase hypermethylation modulated by 17β-estradiol in lung cancer cells. Anticancer Research, 29(7), 2535-2540.

O6-methylguanine-DNA methyltransferase hypermethylation modulated by 17β-estradiol in lung cancer cells. / Lai, Ji Ching; Wu, Jeng Yuan; Cheng, Ya Wen; Yeh, Kun Tu; Wu, Tzu Chin; Chen, Chih Yi; Lee, Huei.

In: Anticancer Research, Vol. 29, No. 7, 07.2009, p. 2535-2540.

Research output: Contribution to journalArticle

Lai, JC, Wu, JY, Cheng, YW, Yeh, KT, Wu, TC, Chen, CY & Lee, H 2009, 'O6-methylguanine-DNA methyltransferase hypermethylation modulated by 17β-estradiol in lung cancer cells', Anticancer Research, vol. 29, no. 7, pp. 2535-2540.
Lai JC, Wu JY, Cheng YW, Yeh KT, Wu TC, Chen CY et al. O6-methylguanine-DNA methyltransferase hypermethylation modulated by 17β-estradiol in lung cancer cells. Anticancer Research. 2009 Jul;29(7):2535-2540.
Lai, Ji Ching ; Wu, Jeng Yuan ; Cheng, Ya Wen ; Yeh, Kun Tu ; Wu, Tzu Chin ; Chen, Chih Yi ; Lee, Huei. / O6-methylguanine-DNA methyltransferase hypermethylation modulated by 17β-estradiol in lung cancer cells. In: Anticancer Research. 2009 ; Vol. 29, No. 7. pp. 2535-2540.
@article{6c43849f670f465181f5dcbb151e5e7e,
title = "O6-methylguanine-DNA methyltransferase hypermethylation modulated by 17β-estradiol in lung cancer cells",
abstract = "Background: Our recent report indicated that MGMT hypermethylation is more common in squamous cell carcinomas (SCC) in males, and smokers than in adenocarcinomas (ADC) infernales, and nonsmokers. More interestingly, MGMT hypermethylation in SCC and ADC was pronouncedly influenced by gender factor, not by smoking status. We questioned whether 17β-estradiol could modulate the machinery of promoter methylation to cause the gender difference of MGMT hypermethylation in lung cancer. Materials and Methods: Two MGMT hypermethylated Ch27 and H1355 lung cancer cell lines were treated with or without 17β-estradiol and the status of hypermethylation was examined by methylated specific methylation (MSP) as compared with both cells treated with demethylating agents, 5-AZA-dC (AZA) or TSA. Results: Our data showed that 17β-estradiol, similar to AZA, diminished the MGMT hypermethylation and restored MGMT mRNA expression, which was not observed in the case of TSA. Western blotting showed that 17β-estradiol markedly reduced DNMT1 expression in Ch27 and H1355 cells, but slightly reduced HDAC1 expression. Consequently, acetylated H3 and H4 histone levels were slightly increased by 17β-estradiol in both cell types. In addition, ChIP analysis revealed that 17β-estradiol simultaneously diminished the binding activity of both proteins on the MGMT promoter of both cell lines. Conclusion: 17β-Estradiol decreased DNMT1 and HDAC1 protein expressions and their binding activity on MGMT promoter, and this may partially contribute to the gender difference of MGMT hypermethylation in lung cancer.",
keywords = "Gender difference, MGMT, NSCLC, p53 mutation",
author = "Lai, {Ji Ching} and Wu, {Jeng Yuan} and Cheng, {Ya Wen} and Yeh, {Kun Tu} and Wu, {Tzu Chin} and Chen, {Chih Yi} and Huei Lee",
year = "2009",
month = "7",
language = "English",
volume = "29",
pages = "2535--2540",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "7",

}

TY - JOUR

T1 - O6-methylguanine-DNA methyltransferase hypermethylation modulated by 17β-estradiol in lung cancer cells

AU - Lai, Ji Ching

AU - Wu, Jeng Yuan

AU - Cheng, Ya Wen

AU - Yeh, Kun Tu

AU - Wu, Tzu Chin

AU - Chen, Chih Yi

AU - Lee, Huei

PY - 2009/7

Y1 - 2009/7

N2 - Background: Our recent report indicated that MGMT hypermethylation is more common in squamous cell carcinomas (SCC) in males, and smokers than in adenocarcinomas (ADC) infernales, and nonsmokers. More interestingly, MGMT hypermethylation in SCC and ADC was pronouncedly influenced by gender factor, not by smoking status. We questioned whether 17β-estradiol could modulate the machinery of promoter methylation to cause the gender difference of MGMT hypermethylation in lung cancer. Materials and Methods: Two MGMT hypermethylated Ch27 and H1355 lung cancer cell lines were treated with or without 17β-estradiol and the status of hypermethylation was examined by methylated specific methylation (MSP) as compared with both cells treated with demethylating agents, 5-AZA-dC (AZA) or TSA. Results: Our data showed that 17β-estradiol, similar to AZA, diminished the MGMT hypermethylation and restored MGMT mRNA expression, which was not observed in the case of TSA. Western blotting showed that 17β-estradiol markedly reduced DNMT1 expression in Ch27 and H1355 cells, but slightly reduced HDAC1 expression. Consequently, acetylated H3 and H4 histone levels were slightly increased by 17β-estradiol in both cell types. In addition, ChIP analysis revealed that 17β-estradiol simultaneously diminished the binding activity of both proteins on the MGMT promoter of both cell lines. Conclusion: 17β-Estradiol decreased DNMT1 and HDAC1 protein expressions and their binding activity on MGMT promoter, and this may partially contribute to the gender difference of MGMT hypermethylation in lung cancer.

AB - Background: Our recent report indicated that MGMT hypermethylation is more common in squamous cell carcinomas (SCC) in males, and smokers than in adenocarcinomas (ADC) infernales, and nonsmokers. More interestingly, MGMT hypermethylation in SCC and ADC was pronouncedly influenced by gender factor, not by smoking status. We questioned whether 17β-estradiol could modulate the machinery of promoter methylation to cause the gender difference of MGMT hypermethylation in lung cancer. Materials and Methods: Two MGMT hypermethylated Ch27 and H1355 lung cancer cell lines were treated with or without 17β-estradiol and the status of hypermethylation was examined by methylated specific methylation (MSP) as compared with both cells treated with demethylating agents, 5-AZA-dC (AZA) or TSA. Results: Our data showed that 17β-estradiol, similar to AZA, diminished the MGMT hypermethylation and restored MGMT mRNA expression, which was not observed in the case of TSA. Western blotting showed that 17β-estradiol markedly reduced DNMT1 expression in Ch27 and H1355 cells, but slightly reduced HDAC1 expression. Consequently, acetylated H3 and H4 histone levels were slightly increased by 17β-estradiol in both cell types. In addition, ChIP analysis revealed that 17β-estradiol simultaneously diminished the binding activity of both proteins on the MGMT promoter of both cell lines. Conclusion: 17β-Estradiol decreased DNMT1 and HDAC1 protein expressions and their binding activity on MGMT promoter, and this may partially contribute to the gender difference of MGMT hypermethylation in lung cancer.

KW - Gender difference

KW - MGMT

KW - NSCLC

KW - p53 mutation

UR - http://www.scopus.com/inward/record.url?scp=69249168007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69249168007&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 2535

EP - 2540

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 7

ER -